Clinical trials are an essential part of research as new drugs and treatments are developed in the fight against cancer. Cancer trials usually compare existing treatments to something thought to be better, so cancer patients always receive at least the best treatment currently available.
Patients seeking treatment at the Skagit Regional Health Cancer Care Center are screened by our clinical trials nurse for enrollment into any appropriate and available trial.
What is a clinical trial?
A clinical trial is a medical research study in which participants volunteer to test new methods to prevent, screen, diagnose, or treat a disease. A clinical trial is also called clinical study or a protocol. All of today’s recognized cancer treatments were proven by clinical trials.
What are the phases of a cancer clinical trial? Cancer clinical trials have four steps, called “phases.” Each one answers a separate research question.
- Phase I trials evaluate safety.
- Phase II trials measure effectiveness.
- Phase III trials test against the best existing treatment.
- Phase IV trials evaluate new uses or long-term effects of the treatment.
What is a "randomized" clinical trial?
In a randomized clinical trial, the participants are assigned by chance to the standard treatment group (control group) or investigational treatment arm. In cancer clinical trials, the control group receives the standard treatment that is currently available.
What is standard therapy?
Standard therapy is a treatment that experts agree is the best practice or best standard of care.
What is the difference between "standard therapy" and "experimental therapy" in a clinical trial?
In medicine, standard therapy is the treatment that experts agree is the standard of care or best practice. In clinical trials, experimental therapy refers to a drug (a new drug, new dose, in combination with other drugs, or a way of giving a drug) or a procedure that has gone through basic lab testing and received approval from the FDA to be tested on human subjects.
Current Clinical Trials
Quit2Heal Study- Testing a Phone App to Help Cancer Patients Quit Smoking
ECOG - ACRIN EAY131 - Molecular Analysis for Therapy Choice (MATCH) Using Foundation One testing through patient Insurance.
Brain and Central Nervous System
NCCTG 0577/RTOG-1071 - Phase III Intergroup Study of Temozolomide Alone Versus Radiotherpy with Concomitant and Adjuvant Temozolomide Versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma (CODEL)
NSABP B-51/RTOG 1304 - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A011502 - Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
A011401 - Randomized Phase III Trial Evaluating th Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
E2112 - A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced breast Cancer
SWOG 1207 - Phase III Randomized Placebo-Controlled Clinical Trial Evaluating The Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-risk Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer
SWOG 1416 - Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT 888(Veliparib) in Metastatic Triple-Negative Breast Cancer And/or BRCA Mutation-Associated Breast Cancer
SWOG 1418 - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvan Chemotherapy
TS-102 Biocompatible (#7627) - Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy. Supplied Agent: TheraSphere
N1048 - A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
GOG 0225/NCT 00719303 - Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Progression-Free Survival?
SWOG 1400 - S1400I - A Phase II/III Randomized Study of Nivolumab plus Ipilimumab vs Nivolumab (No Matching Biomarker Sub Study)
S1400F arm - A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTI-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)
S1400G arm- A Phase II study of TALAZOPARIB (BMN 673) in patients with homologous recombination repair deficiency post Stage IV Squamous Cell Lung Cancer
S1400K arm- A Phase II study of ABBV-399 (Process II) in patients with C-MET Postiive Stage IV or recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)
ALLIANCE A081105 - Randomized Double-Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completed Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). Agent Supplied: Erlotinib.
ALLIANCE A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (screening trial)
GENTLeMEN - Genetic Testing for patients with Metastatic Prostate Cancer
Coalition of Cancer Cooperative Groups
National Cancer Institute
SWOG (a cancer clinical trial cooperative)
Seattle Cancer Care Alliance